October 21, 2022
1 min read
Save
FOURIER-OLE
Issue: October 2022
Long-term safety of evolocumab (Repatha, Amgen) in FOURIER participants.
Long-term safety of evolocumab (Repatha, Amgen) in FOURIER participants.